GGrantIndex
Sort

82,697 grants matching vaccine development

Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk

$949,552
Eva Harris · University Of California Berkeley · U01 · FY2025 · AI

A Novel Probiotic for the Treatment of Sjogren's Syndrome

$949,519
Gary Fanger · Rise Therapeutics, Llc · R44 · FY2020 · DE

Chemically Programmed Immunity

$949,500
Carlos F Barbas · Scripps Research Institute, The · DP1 · FY2010 · OD

Process and Assay Development for cGMP Production and Characterization of a VSV-HIV Vaccine Candidate

$949,225
Eddy Sayed · International Aids Vaccine Initiative · N01 · FY2019 · AI

Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

$949,201
Hilliard Kutscher · Pop Biotechnologies, Inc · R44 · FY2025 · AI

Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure

$948,892
Sharon Riddler · University Of Pittsburgh At Pittsburgh · U01 · FY2025 · AI

Clinical Trials of Haploidentical Hematopoietic Stem Cell Transplantation and Vac

$948,884
Nelson J. Chao · Duke University · P01 · FY2011 · CA

Operations and Management

$948,744
Dennis R. Burton · Scripps Research Institute, The · UM1 · FY2012 · AI

Development of PSMA -based recombinant protein vaccines

$948,449
Progenics Pharmaceuticals, Inc. · R44 · FY2004 · CA

A dual vaccine strategy against filovirus infection

$948,391
Richard W Compans · Emory University · R01 · FY2013 · AI

Novel Stem Cell Immunotherapy for MDR-Tuberculosis

$948,345
Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2025 · AI

A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses

$948,184
Eric Bruening · Tomegavax, Inc. · R44 · FY2016 · CA

The functional significance of CTL escape

$948,180
David I Watkins · University Of Miami School Of Medicine · R01 · FY2019 · AI

Assessing Safety of Cell Substrates and Vaccine Components

$948,167
National Institute Of Allergy And Infectious Diseases · Y01 · FY2010 · AI

Western States Node of the National Drug Abuse Treatment Clinical Trials Network

$948,068
James L. Sorensen · University Of California, San Francisco · UG1 · FY2018 · DA

ADOLESCENT MEDICINE TRIAL NETWORK FOR HIV/AIDS

$948,056
Children'S Research Institute · U01 · FY2001 · HD

Fc effector function in bNAbs

$947,985
Jeffrey Victor Ravetch · California Institute Of Technology · P01 · FY2014 · AI

Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery

$947,948
Kristian Edward Swearingen · Institute For Systems Biology · R01 · FY2025 · AI

Development of highly potent human monoclonal for RSV immuno-prophylaxis

$947,868
Larry Zeitlin · Mapp Biopharmaceutical, Inc. · R44 · FY2022 · AI

Development Of Vaccines For Genital Herpes Simplex Infection

$947,827
Jeffrey Cohen · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

A Novel Probiotic for the Treatment of Sjogren's Syndrome

$947,701
Gary Fanger · Rise Therapeutics, Llc · SB1 · FY2023 · DE

Inhibitors and Probes of HIV-1 Cell Fusion

$947,627
Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK

P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA

$947,589
Larry W Kwak · University Of Tx Md Anderson Can Ctr · P50 · FY2014 · CA

Glycan dependent epitopes of HIV broadly neutralizing antibodies

$947,498
James C. Paulson · Scripps Research Institute, The · R01 · FY2015 · AI

Glycan dependent epitopes of HIV broadly neutralizing antibodies

$947,498
James C. Paulson · Scripps Research Institute, The · R01 · FY2014 · AI